Roche shares pop 4% on $5.3 billion obesity drug deal with Zealand Pharma
Swiss pharmaceutical giant Roche said Wednesday that it had struck a deal worth up to $5.3 billion to develop Zealand ...
AbbVie Is Preparing To Challenge Eli Lilly And Novo Nordisk
AbbVie Inc. enters the obesity market with GUBamy, a promising amylin analog. Click here to find out why ABBV stock is a Buy.
Hosted on MSN2mon
Eli Lilly shares drop as drugmaker cuts revenue guidance on weight loss drug demand
He also noted that the company will add more manufacturing capacity and expects to produce at least 60% more sellable doses of its incretin drugs in the first half of the year compared with the ...
The Financial Express8h
Eli Lilly launches its blockbuster weight loss drug Mounjaro in India
Once-a-weekly, prescription-based medicine, Mounjaro is a single molecule that selectively binds to and activates both GIP ...
Seeking Alpha1mon
Eli Lilly projects 32% revenue growth for 2025, fueled by incretin expansion and new launches
Management expects significant contributions from U.S. incretin class growth and international Mounjaro launches. Earnings per share (EPS) for 2025 are projected at $22.50 to $24.00. Management ...
Hosted on MSN3mon
Corbus, Viking initiated at overweight by Piper Sandler
The bank also sees the drug potentially being combined with incretin therapies. The bank noted that Phase 1 testing for CRB-913 was expected to begin in Q1, with data in the second half of 2025.